

BIO BANKING 2019

14 - 15 FEBRUARY | PORTO, PORTUGAL

- Book your ticket now and **garantee a spot** in this Exclusive Event
- **Limited Offer** to attend this Summit, only 140 seats available
- Follow us on Social Media for the **lastest updates** - #BIOB19

DES- CRIP- TION



On 14 & 15 February 2019, Porto will host the **BioTech Pharma Summit: Biobanking 2019**.

This year event will bring together the world's leading experts in biorepositories, policy makers, and scientific actors to strengthen knowledge in biobanking as well as explore future advances in the field of biosampling for precision medicine, drug development and health research.

Our distinguished panel includes renowned clinicians, researchers, executives and technical professionals from the biopreservation industry as well as the pioneers for a worldwide human research resource. Moreover, the current era is flooded with new advanced technologies, which culminated with the proliferation of more Biobank institutes globally, acting as a clear indicator of a market growth in the field.

Geographically, the EMEA region is estimated to account for a market share of approximately 44% during the predicted period. The presence of a well-established biobanking system in the Nordic countries, such as Sweden, Norway, Denmark, Finland, and Iceland, is a significant factor that bolsters market growth in this region. This conference will gather biobanking leaders from the north, as well as from across the Atlantic, in order to zoom in the market prospects and understand the dynamics of this fast-paced growing industry.

KEY PRACTICAL LEARNING POINTS



- Biobanking innovative models
- Understand the opportunities and challenges of biosampling
- Learn the latest technological methods and procedures for biopreservation, storage stability and validation, while naming evidence-based best practices
- Explore new sample quality management systems, quality standards and accreditation
- Learn how to maintain a sustainable infrastructure in biobanking
- Debate the social and ethical challenges of biobanking for human research
- Predict the market impact of biobanking in the next decade
- Current market trends and future challenges for biobanking success
- Biobanking development in emerging markets
- Prognosis for the Global Biobanking market in an era of transformative new technologies
- Commercial challenges and opportunities
- Redesigning the biobanking business model
- Clinical Trial Strategies in Biobanking and Drug Development

WHO SHOULD ATTEND



Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists and Medical Doctors of:

- Biobanking Researchers
- Biobanking Faculty Members
- Medical Colleges
- Biobanking Associations and Societies
- Training Institutes
- Cryo storage Companies
- Data Privacy and Management Companies
- Security Officers
- Global Biobanking Companies
- Business Developers
- Biobanking investors
- Lab Managers
- Biopharmaceuticals and Biologics Researchers
- Molecular Technologies
- Intellectual property
- Legislation and Policy Advice
- Drug and Safety Assessment
- Market Strategy
- Biopharmaceuticals
- Chief Scientific Officer
- Clinical Immunology
- Drug Safety Assessment & Risk Management
- Population and Disease Based biobanks
- Bioinnovation
- Intellectual property
- Regulatory Affairs
- Health Economics
- Principal Scientists
- Process Control and Analytical Technologies
- Quality Affairs/ Quality Control
- Regulatory Affairs
- Regulatory Compliance
- Legal Affairs
- R & D
- New Product Development
- Quality Affairs/Quality Control
- Health Economics
- Process Control and Analytical Technologies



The BioTech Pharma Summit:

Biobanking 2019 is the leading event to get through the biobanking's ever-thriving market and convenes key stakeholders from the field, and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing timely challenges and best practices for biobanking product success.

We invite all the participants across the globe to join our scientific gathering in Porto, which aims to reveal the newest data and share innovative ideas from research area of bioengineering and tissue preservation.



SPEAKERS LIST



ALI ISMAIL

Founder & Managing Director at Birka Biostorage

SE



ALISSA M. RESCH

Chief Scientific Officer at Coriell Institute for Medical Research

US



ANNETTE AMON-HASSENZÄHL

Clinical Trial Biosample Manager at Merck KGaA

DE



CAOIMHE VALLEY-GILROY

Director, Head of Clinical Trials Biosample Mgmt. at Merck KGaA

DE



CATHERINE LARUE

CEO at IBBL

LU



DIANNE CHADWICK

Manager at University Health Network

CA



IAN POPE

Senior Director at Brooks Life Science Systems

US



JAN-ERIC LITTON

Senior professor at the Karolinska Institutet

SE

Learn the current
market trends and
future challenges only
at the Biobanking 2019.



JIM VAUGHT

Editor-in-Chief,
Biopreservation &
Biobanking

US



KARINE SARGSYAN

Chief Operating
Officer at Biobank
Graz

AT



LAURENT DOLLÉ

Managing Director
of Biothèque
Wallonie Bruxelles

BE



MARYBETH JOSHI

Assistant Director
Biobank & Transla-
tional Research Core
at Duke University
Medical Center

US



MERJA PERÄLÄ

Project Manager
at Auria Biobank

FI



**PEADAR MAC
GABHANN**

Managing Director
at Biostór Ireland

IE



RITA LAWLOR

Biobank and Model
Bank Director at
ARC-NET: Centre
for Applied
Research on Cancer

IT



ROBERT HEWITT

Biobank Consortia
& Communications
at Trans-Hit Bio-
markers

UK

**Over 20 presentations and case studies focusing
on the key areas of the biobanking industry**

including market access strategies, clinical
development, commercialization, biostorage and
biosampling-analytics at the Biobanking 2019.



RONNY BABER

Head of the
LIFE-Biobank and
Preanalytical
Laboratory at
University Hospital
Leipzig

DE



SHONA KERR

Project Manager at
MRC HGU, Univer-
sity of Edinburgh

UK



SOFIA SPYROU

Production Mana-
ger at NIBSC

UK



**SVETLANA GRA-
MATIUK**

President and
Medical Director at
Ukraine Associa-
tion of Biobank

UA



**VINCENT VON
WALCKE-WUL-
FFEN**

CEO at BioKryo
GmbH

DE



SCIENTIFIC AGENDA

Thursday, February 14, 2019

08:00 Registration and Welcome Coffee

08:50 Opening Ceremony by Chairman

BIOBANKING CURRENT STATUS AND FUTURE PROSPECTS

09:00 The changing World of drug Development

By **Laurent Dollé** - Managing Director of Biothèque Wallonie Bruxelles

- > Critical implications of Biobanking
- > Developing Precision Medicine and drug engineering

09:40 Speed Networking

10:10 Establishment of the VISICORT Foundation Biobank for Eye Disease

By **Peadar Mac Gabhann** - Managing Director at Biostór Ireland

- > Sample Management & Quality Control
- > Eye Disease & the Ageing Population
- > Marketing the Biobank

10:50 Morning Coffee and Networking Break

BIOBANKING ETHICAL AND LEGAL FRAMEWORKS

11:30 Balancing the local and the universal in maintaining ethical access to a genomics biobank

By **Shona Kerr** - Project Manager at MRC Human Genetics Unit, Edinburgh

- > Genomics analyses of quantitative traits and electronic health records in consented population-based studies
- > Governing biobanks: data and sample sharing and managed access
- > Are smaller biobanks still useful (and sustainable) in the era of 500,000 plus cohorts?

12:10 Ensuring personal data protection in the EU under current and future regulatory framework

By **Rita Lawlor** - Biobank and Model Bank Director Research Coordinator at ARC-NET: Centre for Applied Research on Cancer

- > Requirements in data protection law and the upcoming General Data Protection Regulation (GDPR) implementation
- > The impact of EU privacy regulations on biobank data collection
- > Requirements for international collaborations.

13:00 Business Lunch

BIOBANKING STRATEGIC DEVELOPMENT

14:00 Business planning and sustainability in biobanking

By **Jim Vaught** - Editor-in-Chief, Biopreservation & Biobanking

14:40 Biobank management model and plan sustainable in developing countries

By **Svetlana Gramatiuk** - President and Medical Director at Ukraine Association of Biobank

- > Biobanking in East Europe
- > The future of the industry in the region

15:20 Afternoon Tea and Networking Break

16:00 How research infrastructures can efficiently contribute to translational/personalised medicine?

By **Catherine Larue** - Chief Executive Officer IBBL

- > Which research infrastructures are making an impact?
- > Impact of the integration of research infrastructures on translational and personalised medicine
- > Building bridges between academic research and health industry, for a better European translational and personalised medicine

16:40 Academic biobanks and industry: overcoming obstacles to efficient collaboration and mutual benefit

By **Robert Hewitt** - Director, Biobank Consortia & Communications at Trans-Hit Biomarkers, Inc.

- > Models of Collaboration and experiences between Bio-Industry and Academic Biobanks
- > Medical information: an essential prerequisite to biomedical research and innovation for both academia and industry

17:20 **Panel Discussion: Protocol and Informed Consent Development**

18:00 Chairman's Closing Remarks

20:00 Gala Dinner

Friday, February 15, 2019

08:00 Registration and Welcome Coffee

08:20 Opening Address from the Chairman

INNOVATIVE FUTURE OF BIOBANKING

08:30 GMP Biobanking in 2020

By **Vincent von Walcke-Wulffen** - CEO at BioKryo GmbH

- > Digitalization
- > Standards
- > Regulatory aspects
- > Data protection

09:10 The Evolving Role of Biobanks: Developing Metrics to Identify Future Needs

By **Alissa M. Resch** - Chief Scientific Officer Coriell Institute for Medical Research

- > Monitor demand for samples and sample utilization
- > Note how changes in technology impact QC workflows and pipelines
- > Track issues to ensure continual process improvements
- > Identify future needs of scientific community to ensure biobank remains relevant
- > Develop metrics for strategic decision-making

BIOBANK DATA & QUALITY MANAGEMENT

09:50 Reproducibility and Reliability of Biobank Data

By **Jan-Eric Litton** - Senior professor at Karolinska Institutet

10:30 Morning Coffee and Networking Break

11:00 How quality biobanking starts during the clinical trial

By **Caoimhe Vallely-Gilroy** - Director, Head of Clinical Trials Biosample Mgmt. at Merck KGaA

Operational challenges and solutions for translating a clinical trial samples into biobank assets

By **Annette Amon-Hassenzahl** - Clinical Trial Biosample Manager at Merck KGaA

11:40 Hospital Biobank Samples and Data for Real-World Evidence Studies

By **Merja Perälä** - Project Manager Auria Biobank

- > Longitudinal sample collections with associated EHR information supporting discovery and development towards personalized medicine
- > RWD based feasibility analyses and patient recruitment for clinical trials

BIOPRESERVATION MODELS IN HUMAN BIOSPECIMEN RESEARCH

12:10 Standardizing terminology and data linking between biorepository, clinical and assay data for downstream analysis

By **Marybeth Joshi** - Assistant Director Biobank & Translational Research Core at Duke University Medical Center

- > Biobank Data Link Biobank Data Linkage & Outcome
- > Follow-up through linkage to health-related records

13:00 Business Lunch

BEST PRACTICES FOR BIOBANKING: COLLECTION, STORAGE, DISTRIBUTION AND USE OF SPECIMENS

14:00 Biobank Graz: Holistic approach to maintain sample quality

By **Karine Sargsyan** - Chief Operating Officer at Biobank Graz

- > Holistic approach is installed focusing on sample quality and integrity

14:40 Risk management in Biorepositories

By **Ali Ismail** - Founder & Director of Commercial Operations at Birka BioStorage

- > Infrastructure, facilities, equipment and logistics. Expectations and deliveries

15:20 Using the best practices for Biobanking

By **Ronny Baber** - Head of the LIFE-Biobank and Preanalytical Laboratory at University Hospital Leipzig

- > High quality biospecimen for reproducible research
- > From epidemiological to healthcare integrated biobanking
- > Influencing factor for liquid biobanked biospecimen

16:00 Afternoon Tea and Networking Break

16:30 Banking of clinical grade human Pluripotent Stem Cells

By **Sofia Spyrou** - Production Manager UK Stem Cell Bank

17:00 **Panel Discussion: Ensuring a healthy future for Biobanking**

17:30 Chairman's Closing Remarks

SPEAKERS BIOGRAPHIES

**IAN POPE, US**

Senior Director at Brooks Life Science Systems



Ian Pope is currently the senior director of the Brooks Cryo group. He has worked in the area of cryogenic systems for over 25 years, initially as managing director of Planer PLC, the original manufacturer of controlled rate freezers. Later, he ran the BioMedical Division of MVE / Chart and co-owned and founded Core Cryolab, a unique bio-repository, cord blood bank and international consulting group based in Toronto Canada. Ian has also worked as Vice President of Cryo Associates in Gaithersburg Maryland. Currently works with and consults for many of the major biological repository operations globally.

**SOFIA SPYROU, UK**

Production Manager at NIBSC



Sofia Spyrou has over six years of experience as a production manager. She joined the UK Stem Cell Bank at NIBSC in 2016 and currently manages the day to day banking operations. Her focus is to review, bank and distribute the MRC funded "EUTCD-Grade" human embryonic stem cell lines. This requires following the Human Tissue Authority's directions on meeting the EU Tissue and Cells Directive. Sofia is responsible for overseeing the complete UK Stem Cell Bank banking process which includes due diligence, banking under GMP conditions, validated QC testing and distributing lines to both national and international customers.

**RITA LAWLOR, IT**

Biobank and Model Bank
Director at ARC-NET: Centre for
Applied Research on Cancer



Rita is co-founder and director of the ARC-Net biobank and coordinates research activities. She is co-PI for the European funded project on "Integrative Analysis of Gene Functions in Cellular and Animal Models of Pancreatic Cancer" and "Biomarkers of tumour recurrence in pancreatic cancer". She is a former director of ISBER and is past president of ESBB, the European, Middle Eastern and African Society for Biopreservation and Biobanking. She is IAPP (International Association of Privacy Professionals) CIPP/E and CIPM certified for European data protection.

**RONNY BABER, DE**

Head of the LIFE-Biobank and
Preanalytical Laboratory at
University Hospital Leipzig



Since 2010 Ronny is the head of the LIFE-Biobank and the LIFE-Preanalytical laboratory (since 2014) in the Leipzig Research Center for Civilisation Diseases (LIFE). Dr. Baber is a member of the working group in the German Institute for Standardization (DIN) which supports the ISO TC 276 responsible for the ISO norm 20387 on biobanking and BBMRI-ERIC workgroups for the evaluation of CEN standards. Since September 2017 he is designated as Treasurer of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB).

**PEADAR MAC GABHANN, IE**

Managing Director at Biostór
Ireland



Peadar joined Schering Plough Corporation and was a key member of staff in the start-up of the first world-wide Biopharma facility in Cork for the production of Interferon in 1983. As Director and board member of Schering Plough Japan, he led the company's research and Asian business development operations. In the past 10 years he co-founded and directed two Life Science start-ups and participated in several international EU FP7 projects. He currently consults with Jacobs Engineering on the design and construction of major Biopharma facilities throughout Europe and runs a certified Tissue Establishment in Ireland.

**MERJA PERÄLÄ, FI**

Project Manager
at Auria Biobank



Merja Perälä joined Auria Biobank at 2017. Auria is Finland's first biobank established in connection with Turku University Hospital and the University of Turku. Merja works as project manager taking care of biobank sample and data request and granting process for research both in academia and industry. From her previous positions Merja has wide experience in scientific research (PhD in Molecular Biology and author in over 50 peer-reviewed publications), project management, and international research funding within university, research institution and private company settings.



KARINE SARGSYAN, AT
*Chief Operating Officer at
Biobank Graz*



Karine worked on and conducted several projects in the health sector with the Ministry of Health and nongovernmental organizations. Since coming to Medical University Graz she worked for the Paediatric Department for a year and has written successful grant proposals collaboratively to fund research in hospital and central laboratory. Currently (since 2012) she is holding also the position of IT manager in Biobank Graz and is/was responsible for acquisition and completion of many effective software programs. Together with her team, since 2007 she developed the Biobank Graz as an interdisciplinary institution.



ROBERT HEWITT, UK
*Biobank Consortia &
Communications at
Trans-Hit Biomarkers*



Dr. Robert Hewitt joined Trans-Hit Bio in November 2017. He is responsible for developing THB's existing international networks of biobanks and for enhancing interactions between industry and academic partners. He holds a medical degree and PhD and has conducted post-doctoral cancer research for 5 years at NIH. He went on to establish biobanks in the UK, Saudi Arabia and Singapore. He was president of ISBER from 2008-2009, and European Editor of the journal Biopreservation and Biobanking from 2009-2015. In 2010 Robert co-founded ESBB and served as executive officer until 2017 when he joined THB.



DIANNE CHADWICK, CA
*Manager at University Health
Network*



Dr. Dianne Chadwick oversees operations of the Biobank at University Health Network (UHN), Canada's largest academic hospital system. Previously she received her PhD in Medical Biophysics from the University of Toronto and completed a fellowship in clinical laboratory genetics. Since joining the UHN Biobank in 2011, Dr. Chadwick has played an active role in its growth and transformation into an institutional core facility supporting high impact research in oncology, multi-organ transplant, cardiovascular and other diseases.



JIM VAUGHT, US
*Editor-in-Chief, Biopreser-
vation & Biobanking*



Dr. Jim Vaught spent 14 years at the U.S. National Cancer Institute, most recently as the Chief of the Biorepositories and Biospecimen Research Branch. In 1999, he was one of the founding members of the International Society for Biological and Environmental Repositories (ISBER) and has served two terms as its president. His current work includes providing biobanking consulting services and serving on a number of advisory boards. He is the current Editor-in-Chief of Biopreservation and Biobanking, the official journal of ISBER.



CAOIMHE VALLEY-GILROY, DE
*Director, Head of Clinical Trials
Biosample Mgmt at Merck KGaA*



Caoimhe is currently the Global Head of Clinical Trial Biosample Management at Merck KGaA, leading a team of biosample operational experts in the feasibility and execution of biosampling strategy in clinical trials, across all trial phases and indications. Caoimhe has previously worked in a variety of clin ops roles across several companies including Roche, Novartis, Actelion and Fisher.



**ANNETTE AMON-
HASSENZEH, DE**
*Clinical Trial Biosample
Manager at Merck KGaA*



Annette is part of the Clinical Trial biosample management group at Merck KGaA and has responsibilities over early and late phase trials. Annette is involved in strategic alliance partnership management of biosample related vendors and is also the representative for risk base monitoring. Previously, Annette has worked for a clinical research organization as Global Clinical Trial Manager.



LAURENT DOLLÉ, BE
*Managing Director of
 Biothèque Wallonie Bruxelles*



After several positions at different Universities or Institutions in Belgium, Laurent has over 16 years of experience working in the Life Sciences field. In 2012, became Assistant Professor at the Free University of Brussels VUB), and developed several skills in stem cells isolation, maintenance and differentiation and was the first to identify liver stem cells from healthy non-manipulated livers by playing with an innovative technique based on Aldehyde dehydrogenase. Laurent Dollé is currently the Operating Director of BWB (Biobanking Wallonia-Brussels; Belgium), which regroups an impressive number of biobanks whose mission is to create and implement a virtual network to unify and make accessible human materials and associated data managed by the biobanks of Wallonia-Brussels' territory.



ALISSA M. RESCH, US
*Chief Scientific Officer at
 Coriell Institute for Medical
 Research*



As head of scientific operations at the Coriell Institute for Medical Research, Dr. Resch oversees the scientific functions of the institute, including management of the contracts & grants portfolio and oversight of the research and project management teams. Prior to her role as Chief Scientific Officer, Alissa served as Director of Biobanking Operations. Before joining Coriell, Alissa was an Assistant Professor of Genetics and Developmental Biology at the University of Connecticut, where she conducted research in the field of RNA and stem cell biology. Alissa earned her PhD from the University of California, Los Angeles and completed a postdoctoral fellowship in Genomics and Bioinformatics at the National Center for Biotechnology Information (NCBI) at the National Institutes of Health.



SHONA KERR, UK
*Project Manager at MRC HGU,
 University of Edinburgh*



Shona has spent the last six years at the University of Edinburgh as project manager of the QTL in Health & Disease programme. Shona sits on the Generation Scotland Access Committee, which has reviewed more than 300 research proposals to ensure that they are scientifically sound, can be supported by the Generation Scotland resource, comply with the aims of biobank and the original consent given by participants. Prior to joining MRC HGU, Shona was the laboratory integration manager for Generation Scotland and directed the implementation of a Laboratory Integration Management System (LIMS) to control sample management from ~24,000 participants across the four Scottish Medical Schools.



ALI ISMAIL, SE
*Founder & Managing
 Director at Birka Biostorage*



Ali Ismail is the founder and the current Managing Director of Birka BioStorage, the global biorepository and biobank, located in Sweden. Ismail started the company in 2010 in Lund, Southern Sweden. Birka's site in Lund is the first certified repository in Scandinavia. The premises are the first cGMP & GDP qualified storage facility in Scandinavia for the banking of biological and pharmaceutical samples. He previously held positions in biotech companies, such as BioInvent International and BioReliance, focusing on process development, GMP manufacturing and safety testing. Since 2014, Ali Ismail started up Resanitec, a clean room control partner company and Insolidex, a CNC workshop company for medical device production.



JAN-ERIC LITTON, SE
*Senior professor
 at the Karolinska Institutet*



Jan-Eric Litton is a Senior professor at the Karolinska Institutet, Stockholm, Sweden. He was appointed BBMRI-ERIC's first Director General on 22 January 2014 - 1 August 2017, building up one of the largest infrastructure for Health in Europe. He was also heading the development of e-epidemiology by using Internet, cell-phones, digital paper and digital TV for collecting epidemiology data. Before, he was the Executive Director and head of one of BBMRI.se. He was the co-director for the Swedish LifeGene initiative, a prospective cohort based biobank. Since 2012 he is part of the e-science initiative in Sweden. Since 2018 he is also the chair for the medical start up company VizzDAT AB.



**VINCENT VON
 WACKE-WULFFEN, DE**
CEO at BioKryo GmbH



Dr. von Walcke-Wulffen studied at the University of Hamburg Business Administration with a minor field of study in chemistry. In 2004 he was a research assistant at the Fraunhofer IBMT in the working group "Cryobank" responsible for legal and administrative aspects of the Fraunhofer Biobank "Eurocryo". Later he become responsible for technical and transport aspects of the biobank. Since 2005 he is the director of the alliance of German Cryobanks e.V. and since 2010 he is founder and managing director of BioKryo GmbH. BioKryo is a GMP-biobank for the storage for cryopreserved samples for later diagnostic and therapeutic use.



CATHERINE LARUE, LU
CEO at IBBL



After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides. She then joined Sanofi Diagnostics Pasteur, at Minneapolis where she was responsible for Assay Development in the immunodiagnostic area. She worked for 7 years as a Director of Business Unit at Bio-Rad. After installing the Biomarkers department in Genfit (Lille, France), she took over the CEO position of the Institute IBBL (Integrated Biobank of Luxembourg) in 2012. She is currently serving as an expert for the European Commission (H2020 and IMI programmes) and for the first Luxembourg Plan Cancer.



SVETLANA GRAMATIUK, UA
President and Medical Director at Ukraine Association of Biobank



Svetlana Gramatiuk serves as President of UAB (Ukraine Associated of Biobank) that she co-founded in 2017. She was also the Medical Director Research Biobank ASK-Health (2015-2016) and the Ukraine Editor of the journal Advanced research biobank and pathophysiology from 2017. Svetlana has also Master of Science Biobanking in Medical University Graz and has an in-depth knowledge of oncology biomarker research in the position holding a from Head Department Medical and Research Laboratory in the Hrigoriev Radiology and Oncology Institute and having completed a Post-Doctoral Fellowship at the Kharkiv National Medical University (Department Pathophysiology from Kharkiv – Ukraine).



MARYBETH JOSHI, US
Assistant Director Biobank & Translational Research Core at Duke University Medical Center



Marybeth has been instrumental in the development, implementation, and management of biospecimen and clinical data repositories and associated experimental data with the ability to transform working hypotheses into fully executable projects with defined benchmarks, goals, and measurable objectives. In 2010, she was asked to partner with Director of the Duke BioBank (now BioDuke) to move forward the institution's goal of developing and implementing Duke University's first enterprise-wide biorepository. Currently, Marybeth serves as the School of Medicine's Standard Terminology Manager for the enterprise-wide biobanking effort.

REGISTRATION FORM

PACKAGE NAME

Title:

Name:

Position:

E-mail:

Title:

Name:

Position:

E-mail:

Company:

Address:

City:

VAT No:

Signature:

Postcode:

Phone

Date:

- -
dd mm yyyy

This booking is invalid without signature

Diogo Lino Ribeiro

Project Director, Europe | Porto Office

EM: diogo.ribeiro@epmgroup.org

PH: +351 915 239 640

ACADEMIC/ MED./ NPO PACKAGE

Individual or Group Registration

2 days Summit ✓

Full-Access to All Sessions ✓

Coffee Breaks/Lunches ✓

Gala Dinner (Extra 50€) ✓

Unique 1-on-1 meetings ✗

Airport Pick-Up/Drop-Off ✗

Accommodation at the Hotel Venue ✗

INDUSTRY BASIC PACKAGE

Individual Registration

2 days Summit ✓

Full-Access to All Sessions ✓

Coffee Breaks/Lunches ✓

Gala Dinner ✓

Unique 1-on-1 meetings ✓

Airport Pick-Up/Drop-Off ✗

Accommodation at the Hotel Venue ✗

INDUSTRY PREMIUM PACKAGE

Individual Registration

2 days Summit ✓

Full-Access to All Sessions ✓

Coffee Breaks/Lunches ✓

Gala Dinner ✓

Unique 1-on-1 meetings ✓

Airport Pick-Up/Drop-Off ✓

Accommodation at the Hotel Venue ✓

	<i>Super Early Bird Until October 19</i>	<i>Early Bird Until November 30</i>	<i>Discounted Ticket Until January 10</i>	<i>Normal Ticket After January 10</i>
Academic/ Med./ NPO Package	500€	600€	650€	850€
Industry Package	1,495€	1,695€	1,795€	1,995€
Premium Package	2,800€	3,000€	3,250€	3,550€

**The Biobanking 2019 is an exclusive limited seat event. Early bird tickets are non-refundable and subject to availability.*

Team Discounts	Until October 19	Until November 30	Until January 10	After January 10
2 Delegates	10%	5%	-	-
3 Delegates	15%	10%	5%	-
4+ Delegates	20%	15%	10%	5%

All Prices displayed include VAT @ The VAT amount will be displayed after the payment process and shown on your invoice.

SPONSORSHIP PACKAGES

GOLD SPONSORSHIP

(VAT INC.) **15,995€**

- › Opportunity to give a speech at the beginning of the conference [up to 40min]
- › 8m2 exhibition space with LCD Monitor for Video Presentations
- › Table & Spiderwall with design customized by the client*
- › FULL page Ad in conference program
- › Company Banner displayed at the all Sessions including Gala Dinner
- › Logo on the conference website and main stage
- › Flyer/promo gifts into congress bags
- › Branding at post-event communication activities
- › Access to all Sessions
- › Business Lunches & Gala Dinner
- › Exclusive One-on-One Meetings
- › **Up to 5 delegates FREE-Admission** (25% discount for extra ticket)
- › VIP Airport Pick-up Service
- › **2 nights** accommodation for 5 delegates registered

SILVER SPONSORSHIP

(VAT INC.) **12,995€**

- › Speaking slot [up to 40min]
- › 6m2 exhibition space with LCD Monitor for Video Presentations
- › Table & Spiderwall with design customized by the client*
- › ½ page Ad in conference program
- › Company Banner displayed at the reception desk & Coffee breaks
- › Logo on the conference website and main stage
- › Flyer/promo gifts into congress bags
- › Branding at post-event communication activities
- › Access to all Sessions
- › Business Lunches & Gala Dinner
- › Exclusive One-on-One Meetings
- › **Up to 4 delegates FREE-Admission** (25% discount for extra ticket)
- › VIP Airport Pick-up Service
- › **2 nights** accommodation for 4 delegates registered

BRONZE SPONSORSHIP

(VAT INC.) **8,995€**

- › Speaking slot [up to 40min]
- › 6m2 exhibition space
- › Table & Spiderwall with design customized by the client*
- › ¼ page Ad in conference program
- › Company Banner displayed at the reception desk
- › Logo on the conference website and main stage
- › Flyer/promo gifts into congress bags
- › Branding at post-event communication activities
- › Access to all Sessions
- › Business Lunches & Gala Dinner
- › Exclusive One-on-One Meetings
- › **Up to 3 delegates FREE-Admission** (25% discount for extra ticket)
- › VIP Airport Pick-up Service
- › **2 nights** accommodation for 3 delegates registered

SPEAKER SPONSORSHIP

(VAT INC.) **5,995€**

- › Speaking slot [up to 40min]
- › 3m2 exhibition space
- › Table & Spiderwall with design customized by the client*
- › Logo on the conference website and main stage
- › Flyer/promo gifts into congress bags
- › Branding at post-event communication activities
- › Access to all Sessions
- › Business Lunches & Gala Dinner
- › Exclusive One-on-One Meetings
- › **Up to 3 delegates FREE-Admission** (25% discount for extra ticket)

KEYNOTE SPEECH PACKAGE

(VAT INC.) **3,550€**

- › Speaking slot [up to 40min]
- › Logo on the conference website and main stage
- › Flyer/promo gifts into congress bags
- › Branding at post-event communication activities
- › Access to all Sessions
- › Business Lunches & Gala Dinner
- › Exclusive One-on-One Meetings
- › **Up to 2 delegates FREE-Admission** (25% discount for extra ticket)

EXHIBITION PACKAGE

(VAT INC.) **3,550€**

- › 3m2 exhibition space
- › Table & Spiderwall with design customized by the client*
- › Logo on the conference website and main stage
- › Flyer/promo gifts into congress bags
- › Branding at post-event communication activities
- › Access to all Sessions
- › Business Lunches & Gala Dinner
- › Exclusive One-on-One Meetings
- › **Up to 2 delegates FREE-Admission** (25% discount for extra ticket)

**Assembly of your space and the design of your booth will be supported by us*

Click bellow to register as a sponsor

By sending this form, I confirm that I have read and accepted the terms and conditions detailed below.

Confirmation

We will confirm your participation after receiving the signed registration form the delegate will receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 weeks before the start of the conference.

Cancellations

Cancellations made one month prior to the start of the conference will be refunded less 50% administration charge. Refunds will be made after the conference. Cancellations made within one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.

Force Majeure

While every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made (including, but not limited to any force majeure occurrence) and provided that the event is not postponed to a later date nor is it merged with another event, the client shall receive a credit note for the amount that the client has paid to such permanently canceled event. No refunds, part refunds or alternative offers shall be made.

Copyright

All Intellectual Property rights in all materials produced or distributed by EPM Group in connection with this event are expressly reserved and any unauthorized duplication, publication or distribution is prohibited.

The biobanking market is expected to reach USD 2.69 Billion by 2022 from USD 1.72 Billion in 2016 at a CAGR of 7.8%. Learn the current market trends and future challenges only at the **Biobanking 2019**

EPMGroup

